



MURDOCH RESEARCH REPOSITORY

<http://researchrepository.murdoch.edu.au>

This is the author's final version of the work, as accepted for publication following peer review but without the publisher's layout or pagination.

Walker, S. and Drummond, P.D. (2011) Implications of a local overproduction of tumor necrosis factor- α in complex regional pain syndrome. Pain Medicine, 12 (12). pp. 1784-1807.

<http://researchrepository.murdoch.edu.au/6478>

Implications of a local over-production of tumor necrosis factor- α in complex regional pain
syndrome

Sabina Walker, Master Appl Sc (Neurosci) and Peter D. Drummond, PhD

School of Psychology, Murdoch University, Perth, Western Australia, Australia

Running title: TNF- α in complex regional pain syndrome

Address for correspondence:

Peter D. Drummond, PhD, School of Psychology, Murdoch University, Perth, Western
Australia 6150, Australia.

Tel: 61-8-9360-2415;

Fax: 61-8-9360-6492;

E-mail: P.Drummond@murdoch.edu.au

**This study was supported by the Australian and New Zealand College of Anaesthetists
and St Jude Medical. Professor Drummond has received research support from Pfizer
Australia. Ms Walker reports no conflicts of interest.**

Abstract

Objective. To review the implications of a local over-production of tumor necrosis factor- α for the pathogenesis and treatment of complex regional pain syndrome.

Background. Elevated local production of tumor necrosis factor- α contributes to prolonged inflammation in the early stages of complex regional pain syndrome. Consequences could include hypoxia and necrosis of local tissues.

Method. We conducted a review of papers published since 2000 on tumor necrosis factor- α in complex regional pain syndrome.

Results. We propose that exaggerated local inflammation, subsequent inhibition of N-type calcium channel currents in sympathetic vasoconstrictor neurons and reduced sympathetic neurotransmitter release from perivascular terminals disrupt sympathetic cutaneous vasoconstrictor activity in complex regional pain syndrome. The resultant microvascular disturbance could exacerbate inflammation in the affected limb. In addition, an under-active cholinergic anti-inflammatory pathway might lead to overproduction of tumor necrosis factor- α . The results of large, randomized controlled treatment studies that test the efficacy of selective anti-tumor necrosis factor- α drugs in complex regional pain syndrome are not yet available. However, numerous small-scale studies and case reports indicate that anti-inflammatory drug treatments that directly or indirectly target tumor necrosis factor- α ameliorate pain and other symptoms in some cases.

Conclusions. An exaggerated inflammatory cytokine cascade may contribute to sensory and autonomic disturbances in complex regional pain syndrome. Further investigation of anti-tumor necrosis factor- α therapy as a cost-effective treatment option for this devastating disease is required. Whether increased activity in the cholinergic anti-inflammatory pathway

provides therapeutic benefits for complex regional pain syndrome also warrants further investigation.

Key Words: complex regional pain syndrome (CRPS); tumor necrosis factor- α (TNF); cholinergic anti-inflammatory pathway; efferent vagus nerve; N-type voltage-gated calcium channels; 'sterile' inflammation

Introduction

Complex regional pain syndrome (CRPS) involves sensory disturbances such as spontaneous stabbing and burning pain, exaggerated stimulus-evoked pain and impaired tactile discrimination in the affected limb; autonomic nervous system dysfunction associated with vascular and sweating abnormalities; trophic changes in skin, hair, nails and bone; motor disturbances resulting in weakness, tremor and dystonia; and persistent edema in the CRPS-affected extremity [1-10]. Symptoms can develop after minimal direct injury to peripheral nerves (termed CRPS type 1), or may be associated with major nerve trunk injury (termed CRPS type 2).

Potential CRPS-inciting events include crush injury, compression injury, ischemia-reperfusion, fracture, contusion (soft tissue injury), sprain, strain, stroke, shock, hypoxia, cardiac ischemia, surgery (usually involving the distal part of an extremity such as carpal tunnel release), invasive procedures (venipuncture, intramuscular injection) and overly tight casting or immobilisation. These events may trigger an inflammatory cascade that results in prolonged and excessive 'sterile' inflammation and, in some unfortunate cases, the development of CRPS [1-13]. Nerve and tissue injury activates mast cells, macrophages and other tissue-resident cells, resulting in the release of inflammatory mediators such as tumor necrosis factor- α (TNF) and histamine and the recruitment of circulating neutrophils and monocytes [14]. Excess local TNF production may then play a key role in perpetuating an exaggerated inflammatory cascade that, if not resolved, triggers painful CRPS.

To explore this question, we conducted a review of papers listed in PubMed since 2000 on TNF in CRPS, supplemented by targeted searches using the Google search engine. In addition, references by key authors and those cited in relevant papers were traced.

This paper begins by providing an overview of the role of TNF in CRPS. We then examine the possibility that excess local TNF might not only mediate chronic inflammation and pain

in CRPS but could also contribute to sympathetic dysfunction and associated vascular deficits. We subsequently review the role of the parasympathetic nervous system in CRPS – specifically the prospect that an under-active cholinergic anti-inflammatory pathway increases the likelihood of TNF over-production and chronic pain. Finally, we examine the efficacy of drugs that directly or indirectly target TNF in CRPS.

TNF in animal models of CRPS

As a master cytokine, TNF has a lead role in activating an inflammatory cytokine cascade that involves release of the pro-inflammatory cytokines interleukin (IL)-1 β , IL-6 and IL-8 [15-18]. Additionally, TNF plays an important part in hypernociception during antigen-induced inflammation [19] and acts on sensory neurons to induce hyperalgesia [20].

Increased TNF levels may also lead to up-regulation of the voltage-gated sodium channels Nav1.3 and Nav1.8 in uninjured dorsal root ganglion neurons following neuronal injury, hence implicating not only injured but also uninjured neurons in neuropathic pain [15,18,21-26].

In a rat model of CRPS type 1 involving distal tibia fracture, increased production of TNF and the inflammatory cytokine cascade was detected in the hindpaw skin of the fractured limb [27-30]. Contributing to this response was substance P-mediated mast cell degranulation, which increased IL-1 β release and contributed to nociceptive sensitization [31]. In addition, tibia fracture led to keratinocyte activation and proliferation, and heightened expression of TNF and other inflammatory mediators in the fractured hindpaw [30]. Conversely, the cytokine inhibitor pentoxifylline decreased cytokine expression and CRPS-like symptoms in this model [32].

The chronic post-ischemia pain (CPIP) model of CRPS involves an ischemia-reperfusion injury induced by a tight tourniquet on the hind limb of anaesthetized rats for three hours.

Removal of the tourniquet results in immediate blood reperfusion, hyperemia, plasma extravasation and edema. CPIP animals demonstrate spontaneous pain, hyperalgesia and allodynia in the affected paw and spread of symptoms to the uninjured hindpaw [4]. This model also involves sympathetic dysfunction, increased activity of the DNA transcription factor nuclear factor κ B (NF κ B) that triggers production of TNF, and high levels of TNF and other pro-inflammatory cytokines. The ischemia-reperfusion injury evokes microvascular disturbances that result in poor tissue perfusion, chronic tissue ischemia and tissue damage with reduced small-diameter nerve fibre endings in the skin and abnormal capillary endothelial cells in skeletal muscle and tibial nerve [4,33-35]. Preventing the translocation of NF κ B into the nucleus inhibits the production of TNF, IL-1 β and cyclooxygenase-2 in macrophages and other immune cells, and impedes the development of hyperalgesia in inflammatory and neuropathic pain models [36-39]. Inhibition of NF κ B also prevents TNF-mediated expression of cell adhesion molecules in endothelial cells, thereby reducing the extravasation of circulating leukocytes and attenuating inflammation [40]. Pyrrolidine dithiocarbamate, a NF κ B antagonist, and free radical scavenger drugs such as N-acetylcysteine and Tempol that reduce NF κ B activation [41-43], decrease signs of hyperalgesia in CPIP rats [4,34,44]. Thus, NF κ B and TNF appear to be pivotal in this model of CRPS.

The TNF receptor 1 is involved in thermal hyperalgesia and mechanical allodynia evoked by chronic constriction injury in mice [45]. Neutralizing antibodies to TNF reduce pain behaviours both in this model and after partial sciatic nerve transection, possibly due to decreased TNF or nerve growth factor in the injured nerve or reduced anterograde transport of TNF in the intact and injured nerves [46,47]. Etanercept, a selective anti-TNF drug, reduces hyperalgesia in the chronic constriction injury model [48] and significantly decreases mechanical allodynia in the spinal cord injury model [49].

Together, these studies indicate that TNF is an important mediator of pain and inflammation in a diverse range of neuropathic pain models, both in studies with minimal direct injury to peripheral nerves that attempt to replicate CRPS type 1, and also after direct injury to peripheral nerves (CRPS type 2).

The role of TNF in CRPS patients

An exaggerated posttraumatic ‘sterile’ inflammatory response that includes a persistently elevated pro-inflammatory cytokine profile, delayed resolution of the inflammatory cascade and depressed anti-inflammatory cytokine expression may contribute to the onset and maintenance of CRPS [17,50-52]. In an elegant study by Üçeyler et al. [50], 42 CRPS patients (median disease duration 12 weeks; range 3 to 70 weeks) were found to have a higher pro-inflammatory cytokine profile than age- and gender-matched healthy controls (n=34). Specifically, CRPS patients had greater pro-inflammatory TNF and IL-2 serum levels and lower anti-inflammatory IL-4 and IL-10 mRNA serum levels than controls. Notably, IL-10 (an anti-inflammatory cytokine) could not be detected in 27 of 42 CRPS patients, whereas pro-inflammatory IL-2 was absent in 32 of 34 controls [50]. Findings from similar studies have confirmed that the early stages of CRPS are characterized by increased pro-inflammatory cytokine activity [6,7,53,54], particularly TNF and IL-6 [55].

It is becoming increasingly clear that *local*, as opposed to *systemic*, inflammation is likely to contribute significantly to CRPS [17,56]. In a study based on 3-phase bone scintigraphy, TNF overproduction was detected in the CRPS-affected hands of three early-stage CRPS patients but not in the contralateral hands or in patients with chronic CRPS [57]. In another study that involved assessing both skin and serum TNF levels, skin punch biopsies and blood samples were taken from 10 patients with osteoarthritis, ten with acute traumatic upper limb bone fracture, and from the affected limb of another ten patients with CRPS type 1 [17]. TNF levels were greater in skin samples from CRPS patients than in skin punch biopsies from the

other patient groups, whereas serum TNF was similar in patients with osteoarthritis and CRPS. Together, these findings signify the importance of locally-produced TNF in the pathogenesis of CRPS. From a practical point of view, the findings also suggest that skin punch biopsies could be used as a minimally invasive diagnostic tool to quantify local TNF levels in the CRPS-affected limb [17].

In association with local leukocyte accumulation [58], the elevated local production of TNF may mediate persistent ‘sterile’ inflammation and tissue damage in the acute CRPS-affected limb [3,59-63]. For example, in a study involving 66 primarily acute-stage patients, higher local TNF and IL-6 levels were observed in most of the induced skin blisters [64]. On the other hand, IL-6 levels in blister fluids of chronic CRPS patients (n=12; median duration=6 years) were significantly reduced compared with levels shortly after CRPS onset, and TNF levels also trended down [65]. Together, these findings suggest that increased TNF, IL-6 and other pro-inflammatory agents are associated with tissue damage, necrosis and pain during the early stages of CRPS, whereas additional mechanisms may contribute later on.

How might locally-increased TNF contribute to tissue damage and necrosis in CRPS?

TNF can stimulate both inflammation and cell death [66]. Thus, poor resolution of a TNF-induced inflammatory cytokine cascade might evoke an exaggerated posttraumatic ‘sterile’ inflammatory response that contributes to symptoms of CRPS [50-52] (Figure 1).

Specifically, excess TNF and other inflammatory cytokines may result in local tissue damage that includes necrosis of sympathetic cutaneous vasoconstrictor and other small-diameter nerve fibers, mitochondrial dysfunction, abnormal endothelial cell activity, poorly-formed capillaries and dysfunctional capillary outgrowth, pericyte damage and skeletal muscle fibre losses in the CRPS-affected limb [67-69]. In turn, hypoactive or degenerating sympathetic efferent fibres could prevent blood from being diverted from arterioles into local capillary beds in CRPS-affected tissue, thereby limiting oxygen and nutritive supply and delaying

waste removal. While the affected extremities of ‘warm limb’ patients may appear flushed and hyperemic, the tissues below the skin could actually be ‘paradoxically ischemic’ [67,70,71]. Indeed, increased skin lactate in CRPS-affected limbs is consistent with tissue ischemia [72]. Local tissue damage could contribute to the maintenance of many CRPS symptoms including neuropathic pain, autonomic dysregulation, motor dysfunction and edema [3,13,67,68,70,71,73-75].

Prolonged production of TNF by macrophages and other immune cells may mediate persistent ‘sterile’ secondary inflammation, pain, severe tissue damage and necrosis [76]. Necrosis involves rapid cell membrane lysis and the passive release of intracellular contents including high mobility group box-1 (HMGB1) protein from the nuclei of necrotic cells [77,78]. HMGB1 interacts with Toll-like receptor 4 expressed by macrophages, activates NF κ B and stimulates further production of TNF and other pro-inflammatory agents, leading to the activation of dendritic and endothelial cells [78-80]. A vicious circle involving extravasation of neutrophils and monocytes from the circulation, activation of macrophages, TNF production and an exaggerated inflammatory cytokine cascade could then result in persistent and excessive ‘sterile’ inflammation in CRPS-affected limbs. The ongoing passive release of excess HMGB1 by necrotic cells may further exacerbate tissue damage and necrosis [81-84] (Figure 1).

Does TNF-mediated inhibition of the N-Type calcium current contribute to impaired sympathetic cutaneous vasoconstriction in CRPS?

Whole-body cooling and warming provokes three distinct patterns of cutaneous blood flow in CRPS patients: increased blood flow and warmth in the symptomatic limb irrespective of body temperature, consistent with impaired sympathetic cutaneous vasoconstriction; decreased flow and coolness in the symptomatic limb irrespective of body temperature; or an intermediate type where the symptomatic limb is warmer or cooler than the contralateral limb

at different body temperatures [85,86]. The cold pattern is most common in CRPS patients with the longest duration of pain [87], possibly due to the development of adrenergic supersensitivity or up-regulation of vasoconstrictors such as endothelin-1 as the condition progresses [61,88,89].

Reductions in venous concentrations of sympathetic neurotransmitters and their metabolites in the warm or cool CRPS-affected limb indicate that sympathetic neurotransmission is compromised in at least some patients [85,90-95]. This may be due to a combination of sympathetic denervation [67] and altered control of sympathetic neural activity [94,96-98]. Although much evidence points toward a central disturbance in regulation of autonomic activity in CRPS [85,93,97-100], a sympathetic deficit distal to the site of trauma may also contribute to local hypoxia and decreased nutritive supply in the CRPS-affected limb [101-103]. In addition, animal models of neuropathic pain suggest that peripheral nerve injury triggers novel sympathetic neurite sprouting. Pathologic coupling between these sprouts and nociceptive neurons in the dorsal root ganglia and upper dermis may underpin sympathetically maintained pain [3,104-107].

An additional mechanism involving excess local TNF production could disrupt sympathetic vasoconstrictor activity in the CRPS-affected extremity. Normal N-type calcium channel function in sympathetic efferent fibres is essential for release of the vasoconstrictor neurotransmitters noradrenaline, ATP and neuropeptide Y [108,109]. In vitro studies have demonstrated that excess TNF stimulates the signaling of transcription factor NF κ B, leading to reduced calcium entry into N-type calcium channels, selective inhibition of the N-type calcium channel current and decreased sympathetic neurotransmitter release from the perivascular terminals of postganglionic sympathetic neurons [110,111] (orange arrows in Figure 1). Selective TNF-mediated inhibition of the N-type calcium channel current in

sympathetic efferents is linked with Crohn's disease and Guillain-Barré syndrome [110-114], but whether this mechanism also contributes to CRPS has yet to be established.

Does impairment of the cholinergic anti-inflammatory pathway play a role in CRPS?

It is widely accepted that an autonomic imbalance that involves the sympathetic nervous system results in altered tissue perfusion and hyper- or hypohidrosis in CRPS. However, there is a paucity of research that investigates whether changes in parasympathetic activity also contribute to autonomic dysfunction or other disturbances in CRPS. Persistently impaired parasympathetic vagal outflow may contribute to cardiovascular disease [115-120], postoperative pain [121], fibromyalgia [122,123], chronic fatigue syndrome, postural orthostatic tachycardia syndrome [124,125], migraine [126], depression [127,128], inflammatory bowel disease [113,114] and various inflammatory autoimmune diseases (rheumatoid arthritis, systemic lupus, primary Sjögren syndrome, polymyalgia rheumatica and scleroderma) [129,130]. Whether vagal outflow is also compromised in CRPS warrants further investigation, as the efferent vagus nerve forms part of the cholinergic anti-inflammatory pathway.

An overview of the cholinergic anti-inflammatory pathway (Figure 2)

Innate immune responses are regulated in various ways via humoral and neural pathways. The humoral pathway controls the release of hormones and cytokines via the hypothalamic-pituitary-adrenal axis. This pathway mediates systemic and local effects on target tissues via circulating anti-inflammatory hormones (corticosteroids, glucocorticoids, IL-10) and tissue repair agents (lipoxins, resolvins) [37,39,81,131]. The neurally-based cholinergic anti-inflammatory pathway, on the other hand, comprises the centrally-controlled efferent arc of the anti-inflammatory reflex. This involves the fine-tuned, targeted and rapid release of acetylcholine into local regions via selected motor branches of the vagus nerve. The efferent

vagus nerve is able to exert systemic and local anti-inflammatory effects in a 'real-time' manner, relative to the slower and more diffuse humoral pathway [37-39,81,131].

Most fibres in the vagus nerve are visceral afferents that supply major organs such as the heart, lungs, liver, spleen and gastrointestinal tract. The remaining 10% - 25% of the vagus nerve comprises efferent fibres that not only provide parasympathetic innervation to the cardiovascular system, liver, spleen, gut and other visceral organs, but also significantly contribute to proper regulation of the cholinergic anti-inflammatory pathway [81,132-134]. Efferent vagal cholinergic release leads to activation of the $\alpha 7$ subunit of the nicotinic acetylcholine receptor expressed by monocytes, macrophages and other cytokine-producing cells (mast cells, B cells, T cells, dendritic cells and microglia), and may also act on vascular endothelial cells and certain neurons.

The afferent arc of the anti-inflammatory reflex fulfils a sensory function by detecting inflammatory stimuli (e.g., IL-1 β) in the periphery via afferent vagal fibres. This leads to glutamate release in the nucleus tractus solitarius (NTS) of the medulla oblongata. The NTS neurons project to numerous central structures involved in pain processing and other functions, including brainstem nuclei (locus coeruleus, rostral ventrolateral medulla, parabrachial nucleus in the pons, nucleus raphe magnus), central nucleus of the amygdala, paraventricular nucleus in the hypothalamus, insular cortex, anterior cingulate cortex and medial prefrontal cortex. The NTS neurons also project via the medial lemniscus to the ventral posterior medial nucleus of the thalamus, and then to the somatosensory cortex in the parietal lobe (parietal superior operculum). Afferent vagal fibres in the NTS project to, and form synapses with, the central terminals of efferent vagal fibres in the dorsal motor nucleus and nucleus ambiguus. Thus, the NTS is a major intersection for afferent and efferent vagal fibres involved in immunomodulation. This neuroanatomical configuration enables the efferent arc of the anti-inflammatory reflex to act reflexively and in a precise manner

following central processing of noxious inflammatory stimuli detected by afferent vagal fibres in the periphery [37-39,81,134-136].

Efferent vagal fibres, immune cells (B cells, T cells, dendritic cells, neutrophils), keratinocytes and vascular endothelial cells all release acetylcholine [37-39,137,138]. Transient exposure to acetylcholine results in $\alpha 7$ -mediated JAK2/STAT3 activation that prevents the translocation of NF κ B from the cytoplasm into the nucleus. This leads to suppression of pro-inflammatory cytokine production by macrophages and other immune cells, without altering the anti-inflammatory cytokine profile (IL-10, corticosterone, transforming growth factor- β) [16,37-39,81,131,139,140]. Conversely, disruption of the efferent arc of the anti-inflammatory reflex may lead to decreased vagal cholinergic outflow and increased pro-inflammatory cytokine production by activated immune cells (Figure 2). If left unchecked, this could result in persistent and exaggerated ‘sterile’ inflammation, tissue injury and necrotic cell death.

As the efferent vagus nerve does not directly innervate the limbs, exactly how the cholinergic anti-inflammatory pathway is able to control inflammation at distal sites is not clear. Nonetheless, in animals with experimentally-induced paw inflammation, vagal nerve stimulation inhibits foot-pad edema [141]. Acetylcholine released from endothelial cells regulates leukocyte trafficking via modulation of adhesion molecule expression [37-39]. Cholinergic agonist-induced activation of the $\alpha 7$ subunit inhibits TNF-induced adhesion molecule expression in human microvascular endothelial cells, hence blocking monocyte and neutrophil adhesion to these cells. This decreases recruitment, extravasation and migration of circulating leukocytes into localized inflamed tissue sites and reduces local TNF production [138,142-144]. Similarly, electrical stimulation of the vagus nerve decreases the activity of circulating dendritic cells and monocytes that release TNF, IL-6 and IL-12 [145].

The efferent vagus nerve targets the spleen via the splenic nerve to modulate both *systemic* and *localized* inflammation [38]. The splenic nerve may deliver specific anti-inflammatory signals that modify circulating neutrophils, monocytes and lymphocytes as they pass through the spleen. Once altered, these circulating white blood cells might then migrate to distal inflamed sites where they exert anti-inflammatory effects. Alternatively, circulating immune cells may no longer be chemo-attracted to distal inflamed regions due to vagally-altered down-regulation of relevant receptors during their transit through the spleen [81,132].

Disruption of the cholinergic anti-inflammatory pathway might contribute to symptoms of CRPS. In support of this possibility, Kohr et al. [146] reported that the serum from a subset of CRPS patients contained surface-binding autoantibodies against autonomic neurons. In particular, autoantibody binding to primary cultured autonomic neurons was detected in 13 of 30 (43.3%) CRPS patients. Furthermore, an inducible surface cholinergic antigen in differentiated SH-SY5Y neuroblastoma cells was recognized by the sera of 18 of 30 CRPS patients [146]. Recent work suggests that autoantibodies in CRPS form a functionally-active subclass of immunoglobulin G, and that the antigens for these agonistic autoantibodies are contained within the second extracellular loop of muscarinic-2 receptors and β_2 -adrenoceptors [147]. Muscarinic M2 receptor agonists may decrease neurogenic inflammation and desensitize nociceptors [148]. In addition, however, central muscarinic acetylcholine receptors play an important role in the activation of the cholinergic anti-inflammatory pathway. In particular, acetylcholine is negatively regulated by the presynaptic M2 autoreceptor in several brain regions. Activation of the M2 autoreceptor (by acetylcholine or other cholinergic agonists) can lead to reduced acetylcholine release in the synaptic cleft in the central terminal of the efferent vagus nerve, leading to decreased central cholinergic neurotransmission and reduced vagal output [149]. As such, agonistic autoantibodies to muscarinic-2 acetylcholine receptors could disrupt vagal outflow in CRPS.

Importantly, significant pain relief was obtained by 3 of 12 CRPS patients following intravenous immunoglobulin treatment to neutralize serum autoantibodies [150] (see below and Table 1). Further research is warranted to clarify the role of autoantibodies in CRPS.

Effect of the cholinergic anti-inflammatory pathway on TNF

The cholinergic anti-inflammatory pathway has been explored extensively in animal models involving ischemia-reperfusion injury and hemorrhagic (circulatory) shock. For example, aortic occlusion restricted blood flow and mediated an exaggerated innate immune response with excess cytokine release. Conversely, vagal nerve stimulation before or after aortic occlusion inhibited the cytokine response [37-39,151]. Similarly, vagal nerve stimulation reversed hypotension, inhibited NF κ B signaling and reduced TNF production in a model that involved clamping the splanchnic arteries for 45 minutes [152]. In a bilateral renal ischemia-reperfusion injury model, pretreatment with nicotine or a selective $\alpha 7$ agonist reduced renal dysfunction and tubular necrosis via decreased TNF production [153]. Finally, vagal outflow provided protection against hemorrhagic (circulatory) shock, likely via decreased translocation of NF κ B into the cell nucleus, reduced TNF synthesis, and decreased hypotension [37-39,154,155].

At present, little is known about the effects of vagal nerve stimulation on hyperalgesia in animal models of neuropathic pain. It may be useful to explore this further, as findings could have important implications for CRPS.

Is TNF a useful target for treating CRPS?

A range of clinical and experimental evidence suggests that anti-inflammatory drug treatments (e.g., corticosteroids) alleviate CRPS by reducing TNF and other inflammatory mediators [15,17,18,50]. Infliximab selectively targets TNF, similar to other TNF monoclonal antibodies (adalimumab, certolizumab pegol, afelimomab and golimumab).

Other drugs not widely appreciated for their anti-inflammatory effects but that nonetheless have demonstrated treatment benefits in CRPS include intravenous immunoglobulin, pregabalin (and gabapentin), thalidomide (and its newer generation derivative lenalidomide), memantine, N-acetylcysteine and bisphosphonate drugs (pamidronate, ibandronate, clodronate, alendronate). Representative examples of treatment studies are listed in Table 1 and described below.

Infliximab has been used to treat lumbar radicular pain including severe sciatica [156-160] and rheumatoid arthritis [161]. Analysis of blister fluid from CRPS-affected limbs of two patients indicated that local concentrations of TNF and IL-6 were significantly decreased following selective anti-TNF (infliximab) treatment. This was accompanied by amelioration of pain, vascular disturbances, edema, motor dysfunction and other symptoms [162]. In addition, a patient with acute CRPS type 1 showed near complete remission following infliximab treatment for eight weeks [163]. Furthermore, a controlled trial involving 13 CRPS type 1 patients showed positive results for the infliximab-treated patients (n=7) compared with the placebo group (n=6) (Netherlands Trial Register 449 ISRCTN 75765780).

Corticosteroid treatment inhibits local inflammation and reduces serum TNF [17]. In a randomized controlled trial that compared corticosteroid (oral prednisolone) to NSAID (oral piroxicam) treatment for up to one month in 60 CRPS patients following stroke, symptoms improved significantly in 25 of the 30 patients who received prednisolone compared with only 5 of the 30 patients in the piroxicam control group [164]. Lasting therapeutic results, including significant pain relief, were reported in other controlled trials and numerous case series following corticosteroid therapy [93,165-175]. Thus, further research involving corticosteroid and other anti-inflammatory (TNF-inhibiting) drug treatments for CRPS appears warranted [176].

Intravenous immunoglobulin not only inhibits certain autoantibodies but may also reduce pro-inflammatory cytokine levels [177] and exert potent anti-inflammatory activity [178]. In particular, intravenous immunoglobulin treatment may result in saturation of macrophage Fc receptors, suppression of pro-inflammatory mediators (TNF, macrophage colony-stimulating factor and monocyte chemoattractant protein-1), up-regulation of anti-inflammatory cytokines and inhibition of endothelial cell activation and inflammation [179-184]. This treatment was recently reported to decrease immune activation, reduce pain and improve autonomic disturbances in patients with CRPS [150].

Pregabalin (and gabapentin) is approved for treatment of post herpetic neuralgia and painful diabetic peripheral neuropathy, and may also be prescribed 'off-label' for CRPS and other neuropathic pain conditions. Varying degrees of success with this drug have been reported for CRPS [185-189]. Pregabalin (and gabapentin) bind with the $\alpha 2\delta 1$ calcium channel subunit, leading to inhibition of translocation of NF κ B into the cell nucleus and reduced gene transcription for inflammatory agents including IL-6 [190,191] and (likely) TNF.

Thalidomide offers various degrees of relief in CRPS patients [192-198]. Lenalidomide, an analogue with greater potency and less toxicity, also extends certain benefits for some CRPS patients. Specifically, 14 of 40 CRPS patients who took oral lenalidomide treatment for more than 2 years showed overall improvement in symptoms including improvements in pain, allodynia and sleep [199]. An earlier study reported similar results following 12-week lenalidomide treatment [200]. The therapeutic effects may be mediated by degradation of TNF mRNA [50]. Thalidomide also inhibits TNF-induced NF κ B activation, hence preventing further TNF synthesis [201,202]. Due to known risks of severe teratogenicity, availability of thalidomide is limited to patients beyond child-bearing age.

Promising results have also been reported for memantine and memantine/morphine treatment in CRPS patients. Specifically, pain decreased in three CRPS patients following 8-week oral memantine treatment [203] and in six CRPS patients in a follow-up study [204]. More recently, 10 CRPS patients benefited significantly following memantine/morphine combination treatment [205]. As administration of memantine hydrochloride decreases TNF expression in animals [206], studies are warranted to determine whether memantine decreases local TNF in CRPS patients (in addition to effects on NMDA and other receptors). N-acetylcysteine may also benefit certain ‘cold’ CRPS type 1 patients [207] by inhibiting NF κ B translocation and reducing TNF production [41,43].

Bisphosphonate treatment evokes apoptosis of macrophages and macrophage-derived osteoclasts, and decreases production of TNF and other inflammatory mediators in vitro and in vivo [208-213]. A pilot study involving ibandronate (a third generation amino-bisphosphonate) indicated that pain ratings decreased in patients with upper limb CRPS [214]. Numerous studies involving bisphosphonates, including pamidronate, clodronate and alendronate treatment, have demonstrated varying degrees of success in CRPS patients [198,215-232].

Together, the findings reviewed above suggest that drugs that reduce the availability of TNF and other inflammatory cytokines contribute significantly to the amelioration of pain and ‘sterile’ inflammation in CRPS. As such, the ability to block TNF may play a key role in the treatment of pain and edema in CRPS. It is noteworthy that complete remission from CRPS was reported in small subset of patients following TNF-inhibiting drug treatment (Table 1).

Although effective in some cases, drug treatments that target TNF may increase the risk of secondary infections or other adverse events. Hence, it is important to establish whether prolonged stimulation of the cholinergic anti-inflammatory pathway decreases TNF production and ameliorates symptoms in CRPS. Non-invasive techniques that increase vagal

outflow include acupuncture, controlled deep breathing (via deep breathing exercises, yoga, Tai Chi, Qigong) and meditation [81,122,233-235]. Benefits of diaphragmatic breathing exercises, mental imagery, music therapy, hydrotherapy, proprioception training, tactile desensitisation (for allodynia), physical/gym rehabilitation, recreational/socialisation therapy, massage, relaxation (for stress management) and problem solving/assertiveness training have been reported for children with CRPS [236]. Whether these treatment gains involve increased vagal outflow or reductions in TNF is unknown.

Conclusions

Increased local production of TNF may contribute to the onset and maintenance of CRPS by promoting chronic ‘sterile’ inflammation and secondary microvascular disturbances including impaired sympathetic cutaneous vasoconstriction. Thus, it may be desirable to reduce local TNF levels by means of selective anti-TNF drug treatment or via pharmacological, electrical or non-invasive stimulation of the cholinergic anti-inflammatory pathway. From an experimental and clinical perspective, research into anti-TNF therapy may offer additional insights into the pathogenesis of CRPS, and result in the development of cost-effective treatment options for this devastating disease.

References

1. Jänig W, Baron R. Complex regional pain syndrome is a disease of the central nervous system. *Clin Auton Res* 2002; 12: 150-64.
2. Jänig W, Baron R. Complex regional pain syndrome: mystery explained? *Lancet Neurol* 2003; 2: 687-97.
3. de Mos M, Sturkenboom MCJM, Huygen, FJPM. Current understandings on complex regional pain syndrome. *Pain Practice* 2009; 9: 86-99.
4. Coderre TJ, Bennett GJ. A hypothesis for the cause of complex regional pain syndrome-type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology. *Pain Med* 2010; 11: 1224–38.
5. Jänig W. The fascination of complex regional pain syndrome. *Exp Neurol* 2010; 221: 1-4.
6. Maihöfner CF, Seifert F, Markovic K. Complex regional pain syndromes: new pathophysiological concepts and therapies. *Eur J Neurol* 2010; 17: 649–60.
7. Naleschinski D, Baron R. Complex regional pain syndrome type I: neuropathic or not? *Curr Pain Headache Rep* 2010; 14: 196-202.
8. Harden RN. Objectification of the diagnostic criteria for CRPS. *Pain Med* 2010; 11: 1212–5.
9. Bruehl S. An update on the pathophysiology of complex regional pain syndrome. *Anesthesiology* 2010; 113: 713-25.
10. Marinus J, Moseley GL, Birklein F, Baron R, Maihöfner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. *Lancet Neurol* 2011; 10: 637-48.
11. Wasner G, Schattschneider J, Binder A, Baron R. Complex regional pain syndrome - diagnostic, mechanisms, CNS involvement and therapy. *Spinal Cord*, 2003; 41: 61-75.

12. de Mos M, Huygen FJ, Dieleman JP, Koopman JS, Stricker BH, Sturkenboom MC. Medical history and the onset of complex regional pain syndrome (CRPS). *Pain* 2008; 139: 458–66.
13. Groeneweg G, Huygen FJPM, Coderre TJ, Zijlstra FJ. Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management. *BMC Musculoskelet Disord* 2009; 10: 116.
14. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. *Brain Res Rev* 2006; 51: 240-64.
15. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. *Nat Rev Neurosci* 2005; 6: 521–32.
16. Zwergal A, Quirling M, Saugel B, Huth KC, Sydlik C, Poli V, Neumeier D, Ziegler-Heitbrock HW, Brand K. C/EBP β blocks p65 phosphorylation and thereby NF- κ B-mediated transcription in TNF-tolerant cells. *J Immunol* 2006; 177: 665-72.
17. Krämer HH, Eberle T, Üçeyler N, Wagner I, Klonschinsky T, Müller LP, Sommer C, Birklein F. TNF- α in CRPS and ‘normal’ trauma – significant differences between tissue and serum. *Pain* 2010 (in press).
18. Leung L, Cahill CM. TNF- α and neuropathic pain - a review. *J Neuroinflamm* 2010; 7: 27.
19. Cunha TM, Verri WA, Valerio DA, Guerrero AT, Nogueira LG, Vieira SM, Souza DG, Teixeira MM, Poole S, Ferreira SH, Cunha FQ. Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice. *Eur J Pain* 2008; 12: 1059-68.
20. Parada CA, Yeh JJ, Joseph EK, Levine JD. Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat. *Eur J Neurosci* 2003; 17: 1847-52.

21. Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor- α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. *J Neurosci* 2003; 23: 2517-21.
22. Svensson CI, Schäfers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. *Neurosci Lett* 2005; 379: 209-13.
23. Jin X, Gereau RW. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor- α . *J Neurosci* 2006; 26: 246–55.
24. Dussor G. Changes in undamaged fibers following peripheral nerve injury: a role for TNF- α . *Pain* 2010; 151: 237-8.
25. He X-H, Zang Y, Chen X, Pang R-P, Xu J-T, Zhou X, Wei X-H, Li Y-Y, Xin W-J, Qin Z-H, Liu X-G. TNF- α contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury. *Pain* 2010; 151: 266-79.
26. Ibeakanma C, Vanner S. TNF α is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons. *Gut* 2010; 59: 612-21.
27. Sabsovich I, Guo TZ, Wei T, Zhao R, Li X, Clark DJ, Geis C, Sommer C, Kingery WS. TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I. *Pain* 2008; 137: 507-19.
28. Li WW, Sabsovich I, Guo TZ, Zhao R, Kingery WS, Clark JD. The role of enhanced cutaneous IL-1 β signaling in a rat tibia fracture model of complex regional pain syndrome. *Pain* 2009; 144: 303-13.
29. Kingery WS. Role of neuropeptide, cytokine, and growth factor signaling in complex regional pain syndrome. *Pain Med* 2010; 11: 1239–50.

30. Li WW, Guo TZ, Li XQ, Kingery WS, Clark JD. Fracture induces keratinocyte activation, proliferation, and expression of pro-nociceptive inflammatory mediators. *Pain* 2010; 151: 843-52.
31. Kingery W, Li W, Guo T, Liang D, Clark J. Substance P signaling controls mast cell activation, degranulation, IL-1 cytokine expression, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. IASP (Montreal) 2010, PM 193.
32. Wei T, Sabsovich I, Guo TZ, Shi X, Zhao R, Li W, Geis C, Sommer C, Kingery WS, Clark DJ. Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. *Eur J Pain* 2009; 13: 253-62.
- 33.Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic post-ischemia pain (CPIP): a novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. *Pain* 2004; 112: 94–105.
34. de Mos M, Laferrière A, Millecamps M, Pilkington M, Sturkenboom MC, Huygen FJ, Coderre TJ. Role of NFκB in an animal model of complex regional pain syndrome–type I (CRPS-I). *J Pain* 2009; 10: 1161-9.
35. Coderre TJ. An animal model suggests microvascular dysfunction and chronic tissue ischemia contribute to CRPS-1. *Eur J Pain Suppl* 2010; 4: 8.
36. Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M, Geisslinger G. Specific inhibition of IκB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. *J Neurosci* 2004; 24: 1637–45.
37. Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. *J Intern Med* 2009; 265: 663-79.

38. Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. *Neuron* 2009; 64: 28-32.
39. Tracey KJ. Reflex control of immunity. *Nat Rev Immunol* 2009; 9: 418-28.
40. Rajan S, Ye J, Bai S, Huang F, Guo Y-L. NF- κ B, but not p38 MAP kinase, is required for TNF- α -induced expression of cell adhesion molecules in endothelial cells. *J Cell Biochem* 2008; 105: 477–86.
41. Kim H, Seo JY, Roh KH, Lim JW, Kim KH. Suppression of NF- κ B activation and cytokine production by N-acetylcysteine in pancreatic acinar cells. *Free Radical Biol Med* 2000; 29: 674-683.
42. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Caputi AP, Thiemermann C. Tempol reduces the activation of nuclear factor- κ B in acute inflammation. *Free Radic Res* 2004; 38: 813-9.
43. Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. *Mediat Inflamm* 2008; 2008: 716458.
44. Laferrière A, Millecamps M, Xanthos DN, Xiao WH, Siau C, de Mos M, Sachot C, Ragavendran JV, Huygen FJ, Bennett GJ, Coderre TJ. Cutaneous tactile allodynia associated with microvascular dysfunction in muscle. *Mol Pain* 2008; 4: 49.
45. Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. *Exp Neurol* 1998; 151: 138-42.
46. Sommer C, Lindenlaub T, Teuteberg P, Schäfers M, Hartung T, Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. *Brain Res* 2001; 913: 86-9.
47. Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). *Neurosci Lett* 2008; 437: 199-202.

48. Sommer C, Schäfers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. *J Periph Nerv Sys* 2001; 6: 67-72.
49. Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, McMahon SB. Effects of etanercept and minocycline in a rat model of spinal cord injury. *Eur J Pain* 2009; 13: 673-81.
50. Üçeyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. *Pain* 2007; 132: 195-205.
51. Üçeyler N, Sommer C. Cytokine-induced pain: basic science and clinical implications. *Rev Analgesia* 2007; 9: 87–103.
52. Üçeyler N, Schäfers M, Sommer C. Mode of action of cytokines on nociceptive neurons. *Exp Brain Res* 2009; 196: 67-78.
53. Maihöfner C, Handwerker HO, Neundorfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-alpha? *Neurology* 2005; 65: 311–3.
54. Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M. Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. *Clin J Pain* 2006; 22: 235-9.
55. Harden RN. Cytokine imbalance/activity as a unifying hypothesis for the pathogenesis and pathophysiology of complex regional pain syndrome? *Pain* 2010 (in press).
56. Schinkel C, Scherens A, Koller M, Roellecke G, Muhr G, Maier C. Systemic inflammatory mediators in post-traumatic complex regional pain syndrome (CRPS I) — longitudinal investigations and differences to control groups. *Eur J Med Res* 2009; 14: 130–5.
57. Bernateck M, Karst M, Gratz KF, Meyer GJ, Fischer MJ, Knapp WH, Koppert W, Brunkhorst T. The first scintigraphic detection of tumor necrosis factor-alpha in patients with complex regional pain syndrome type 1. *Anesth Analg* 2010; 110: 211-5.

58. Tan ECTH, Oyen WJG, Goris RJA. Leukocytes in complex regional pain syndrome type I. *Inflammation* 2005; 29: 182-186.
59. Huygen FJPM, de Bruijn AGJ, De Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. *Mediators Inflamm* 2002; 11: 47–51.
60. Huygen FJPM, Ramdhani N, van Toorenenbergen A, Klein J, Zijlstra FJ. Mast cells are involved in inflammatory reactions during complex regional pain syndrome type 1. *Immunol Lett* 2004; 91: 147–54.
61. Munnikes RJ, Muis C, Boersma M, Heijmans-Antonissen C, Zijlstra FJ, Huygen F. Intermediate stage complex regional pain syndrome type 1 is unrelated to proinflammatory cytokines. *Mediators Inflamm* 2005; 2005: 366–72.
62. Groeneweg JG, Huygen FJPM, Heijmans-Antonissen C, Niehof S, Zijlstra FJ. Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. *BMC Musculoskelet Disord* 2006; 7: 91.
63. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJM, Huygen FJPM, van der Meijden P, Hop WCJ, Hooijkaas H, Zijlstra FJ. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. *Mediators Inflamm* 2006; 2006:1–8.
64. Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Tumor necrosis factor- α and interleukin-6 are not correlated with the characteristics of complex regional pain syndrome type 1 in 66 patients. *Eur J Pain* 2008; 12: 716–21.
65. Wesseldijk F, Huygen FJPM, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Six years follow-up of the levels of TNF- α and IL-6 in patients with complex regional pain syndrome type 1. *Mediators Inflamm* 2008; 2008: 469439.

66. Kantari C, Walczak H. Dual philosophy in death receptor signalling. *Open Cell Signaling J* 2011; 3: 27-34.
67. Albrecht PJ, Hines S, Eisenberg E, Pud D, Finlay DR, Connolly MK, Pare M, Davar G, Rice FL. Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. *Pain* 2006; 120: 244–66.
68. Oaklander AL, Rissmiller JG, Gelman LB, Zheng L, Chang Y, Gott R. Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). *Pain* 2006; 120: 235–43.
69. Tan ECTH, Janssen AJM, Roestenberg P, van den Heuvel LP, Goris RJA, Rodenburg RJT. Mitochondrial dysfunction is involved in the pathophysiology of complex regional pain syndrome type I. In: *Clinical and Fundamental Aspects of Complex Regional Pain Syndrome Type I*. Tan ECTH, Doctoral Thesis Radboud University Nijmegen Medical Centre, 2010.
70. Oaklander AL, Fields HL. Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy? *Ann Neurol* 2009; 65: 629-38.
71. Oaklander AL. Role of minimal distal nerve injury in complex regional pain syndrome-I. *Pain Med* 2010; 11: 1251–1256.
72. Birklein F, Weber M, Neundorfer B. Increased skin lactate in complex regional pain syndrome: evidence for tissue hypoxia? *Neurology* 2000; 55: 1213-5.
73. van der Laan L, ter Laak HJ, Gabreels-Festen A, Gabreels F, Goris RJ. Complex regional pain syndrome type I (RSD): pathology of skeletal muscle and peripheral nerve. *Neurology* 1998; 51: 20–5.
74. Hulsman NM, Geertzen JH, Dijkstra PU, van den Dungen JJ, den Dunnen WF. Myopathy in CRPS-I: disuse or neurogenic? *Eur J Pain* 2009; 13: 731-6.

75. Tan ECTH, ter Laak HJ, Hopman MTE, van Goor H, Goris RJA. Impaired oxygen utilization in skeletal muscle of CRPS1 patients. In: Clinical and Fundamental Aspects of Complex Regional Pain Syndrome Type I. Tan ECTH, Doctoral Thesis Radboud University Nijmegen Medical Centre, 2010.
76. Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004; 116: 491-7.
77. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT. Diabetes-enhanced tumor necrosis factor- α production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 2008; 172: 1411-18.
78. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol Mech Dis 2008; 3: 99-126.
79. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565–70.
80. Shibasaki M, Sasaki M, Miura M, Mizukoshi K, Ueno H, Hashimoto S, Tanaka Y, Amaya F. Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain 2010; 149: 514-21.
81. Tracey KJ. Understanding immunity requires more than immunology. Nat Immunol 2010; 11: 561-4.
82. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. PNAS 2010; 107: 11942-7.

83. Yang H, Rosas M, Ochani M, Li J, Lu B, Olofsson P, Chavan S, Tracey K. Toll-like receptor 4 (TLR4) and interferon-gamma (IFN- γ) are required for HMGB1-induced TNF release from macrophages. *J Immunol* 2010; 184: 34.18.
84. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. *Biochimica et Biophysica Acta (BBA)* 2010; 1799: 149-56.
85. Wasner G, Schattschneider J, Heckmann K, Maier C, Baron R. Vascular abnormalities in reflex sympathetic dystrophy (CRPS I): mechanisms and diagnostic value. *Brain* 2001; 124: 587–99.
86. Krumova EK, Frettlöh J, Klauenberg S, Richter H, Wasner G, Maier C. Long term skin temperature measurements – a practical diagnostic tool in complex regional pain syndrome. *Pain* 2008; 140: 8–22.
87. Birklein F, Riedl B, Sieweke N, Weber M, Neundorfer B. Neurological findings in complex regional pain syndromes--analysis of 145 cases. *Acta Neurol Scand* 2000; 101: 262-9.
88. Groeneweg JG, Heijmans-Antonissen C, Huygen FJPM, Zijlstra FJ. Expression of endothelial nitric oxide synthase and endothelin-1 in skin tissue from amputated limbs of patients with complex regional pain syndrome. *Mediators Inflamm* 2008; 680981: 1-5.
89. Drummond PD. Sensory disturbances in complex regional pain syndrome: clinical observations, autonomic interactions, and possible mechanisms. *Pain Med* 2010; 11: 1257–66.
90. Drummond PD, Finch PM, Smythe GA. Reflex sympathetic dystrophy: the significance of differing plasma catecholamine concentrations in affected and unaffected limbs. *Brain* 1991; 114: 2025-36.

91. Drummond PD, Finch PM, Edvinsson L, Goadsby PJ. Plasma neuropeptide Y in the symptomatic limb of patients with causalgic pain. *Clin Auton Res* 1994; 4: 113–6.
92. Harden RN, Duc TA, Williams TR, Coley D, Cate JC, Gracely RH. Norepinephrine and epinephrine levels in affected versus unaffected limbs in sympathetically maintained pain. *Clin J Pain* 1994; 10: 324–30.
93. Wasner G, Heckmann K, Maier C, Baron R. Vascular abnormalities in acute reflex sympathetic dystrophy (CRPS I): complete inhibition of sympathetic nerve activity with recovery. *Arch Neurol* 1999; 56: 613-20.
94. Goldstein DS, Tack C, Li S-T. Sympathetic innervation and function in reflex sympathetic dystrophy. *Ann Neurol* 2000; 48: 49-59.
95. Haensch C-A, Jörg J, Lerch H. I-123-metaiodobenzylguanidine uptake of the forearm shows dysfunction in peripheral sympathetic mediated neurovascular transmission in complex regional pain syndrome type I (CRPS I). *J Neurol* 2002; 249: 1742-3.
96. Drummond PD, Skipworth S, Finch PM. alpha 1-adrenoceptors in normal and hyperalgesic human skin. *Clin Sci (Lond)* 1996; 91: 73-7.
97. Wasner G. Dysfunction of the autonomic nervous system. *Eur J Pain Suppl* 2010; 4: 8.
98. Wasner G. Vasomotor disturbances in complex regional pain syndrome— a review. *Pain Med* 2010; 11: 1267–73.
99. Arnold JM, Teasell RW, MacLeod AP, Brown JE, Carruthers SG. Increased venous alpha-adrenoceptor responsiveness in patients with reflex sympathetic dystrophy. *Ann Intern Med* 1993; 118: 619-21.
100. Birklein F, Riedl B, Neundörfer B, Handwerker HO. Sympathetic vasoconstrictor reflex pattern in patients with complex regional pain syndrome. *Pain* 1998; 75: 93-100.

101. Kurvers HA, Jacobs MJ, Beuk RJ, van den Wildenberg FA, Kitslaar PJ, Slaaf DW, Reneman RS. Reflex sympathetic dystrophy: result of autonomic denervation? Clin Sci (Lond) 1994; 87: 663-9.
102. Kurvers HA, Jacobs MJ, Beuk RJ, van den Wildenberg FA, Kitslaar PJ, Slaaf DW, Reneman RS. Reflex sympathetic dystrophy: evolution of microcirculatory disturbances in time. Pain 1995; 60: 333-40.
103. Kurvers HA, Hofstra L, Jacobs MJ, Daemen MA, van den Wildenberg FA, Kitslaar PJ, Slaaf DW, Reneman RS. Reflex sympathetic dystrophy: does sympathetic dysfunction originate from peripheral neuropathy? Surgery 1996; 119: 288-96.
104. McLachlan EM, Jänig W, Devor M, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993; 363: 543-6.
105. Jänig W, Levine JD, Michaelis M. Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. Prog Brain Res 1996; 113: 161-84.
106. Michaelis M, Devor M, Jänig W. Sympathetic modulation of activity in rat dorsal root ganglion neurons changes over time following peripheral nerve injury. J Neurophysiol 1996; 76: 753-63.
107. Ruocco I, Cuello AC, Ribeiro-Da-Silva A. Peripheral nerve injury leads to the establishment of a novel pattern of sympathetic fibre innervation in the rat skin. J Comp Neurol 2000; 422: 287-96.
108. Brock JA, Cunnane TC. Effects of Ca²⁺ concentration and Ca²⁺ channel blockers on noradrenaline release and purinergic neuroeffector transmission in rat tail artery. Br J Pharmacol 1999; 126: 11-8.
109. Morris JL, Ozols DI, Lewis RJ, Gibbins IL, Jobling P. Differential involvement of N-type calcium channels in transmitter release from vasoconstrictor and vasodilator neurons. Br J Pharmacol 2004; 141: 961-70.

110. Motagally MA, Lukewich MK, Chisholm SP, Neshat S, Lomax AE. Tumour necrosis factor alpha activates nuclear factor kappaB signalling to reduce N-type voltage-gated Ca²⁺ current in postganglionic sympathetic neurons. *J Physiol* 2009; 587: 2623–34.
111. Motagally MA, Neshat S, Lomax AE. Inhibition of sympathetic N-type voltage-gated Ca²⁺ current underlies the reduction in noradrenaline release during colitis. *Am J Physiol Gastrointest Liver Physiol* 2009; 296: 1077-84.
112. Lomax AE, O'Reilly M, Neshat S, Vanner SJ. Sympathetic vasoconstrictor regulation of mouse colonic submucosal arterioles is altered in experimental colitis. *J Physiol* 2007; 583: 719–30.
113. Boissé L, Chisholm SP, Lukewich MK, Lomax AE. Clinical and experimental evidence of sympathetic neural dysfunction during inflammatory bowel disease. *Clin Exp Pharmacol Physiol* 2009; 36: 1026-33.
114. Lomax AE, Sharkey KA, Furness JB. The participation of the sympathetic innervation of the gastrointestinal tract in disease states. *Neurogastroenterol Motil* 2010; 22: 7–18.
115. Sosnowski M, MacFarlane PW, Czyz Z, Skrzypek-Wanha J, Boczkowska-Gaika E, Tendera M. Age-adjustment of HRV measures and its prognostic value for risk assessment in patients late after myocardial infarction. *Int J Cardiol* 2002; 86: 249–58.
116. Krämer HH, Rolke R, Bickel A, Birklein F. Thermal thresholds predict painfulness of diabetic neuropathies. *Diabetes Care* 2004; 27: 2386–91.
117. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. *Biol Psychol* 2007; 74: 224–42.
118. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. *Psychoneuroendocrinology* 2008; 33: 1305-12.

119. von Känel R, Orth-Gomér K. Autonomic function and prothrombotic activity in women after an acute coronary event. *J Women's Health* 2008; 17: 1331-7.
120. Ermis N, Gullu H, Caliskan M, Unsal A, Kulaksizoglu M, Muderrisoglu H. Gabapentin therapy improves heart rate variability in diabetic patients with peripheral neuropathy. *J Diabetes Complications* 2010; 24: 229-33.
121. Nielsen R, Nikolajsen L, Krøner K, Mølgaard H, Vase L, Jensen TS, Terkelsen AJ. Preoperative reduced parasympathetic activity predicts postoperative pain in patients undergoing open carpal tunnel surgery. *IASP (Montreal) 2010*, PM 056.
122. Hassett AL, Radvanski DC, Vaschillo EG, Vaschillo B, Sigal LH, Karavidas KK, Buyske S, Lehrer PM. A pilot study of the efficacy of heart rate variability (HRV) biofeedback in patients with fibromyalgia. *Appl Psychophysiol Biofeedback* 2007; 32: 1-10.
123. Staud R. Heart rate variability as a biomarker of fibromyalgia syndrome. *Fut Rheumatol* 2008; 3: 475-83.
124. Stewart JM. Autonomous nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. *Pediatr Res* 2000; 48: 218-26.
125. Wyller VB, Barbieri R, Thaulow E, Saul JP. Enhanced vagal withdrawal during mild orthostatic stress in adolescents with chronic fatigue. *Ann Noninvasive Electrocardiol* 2008; 13: 67-73.
126. Bäcker M, Grossman P, Schneider J, Michalsen A, Knoblauch N, Tan L, Niggemeyer C, Linde K, Melchart D, Dobos GJ. Acupuncture in migraine: investigation of autonomic effects. *Clin J Pain* 2008; 24: 106-15.

127. Karavidas M. Heart rate variability biofeedback for major depression. *Biofeedback* 2008; 36: 18–21.
128. Siepmann M, Aykac V, Unterdörfer J, Petrowski K, Mueck-Weymann M. A pilot study on the effects of heart rate variability biofeedback in patients with depression and in healthy subjects. *Appl Psychophysiol Biofeedback* 2008; 33: 195-201.
129. Stojanovich L, Milovanovich B, de Luka SR, Popovich-Kuzmanovich D, Bisenich V, Djukanovich B, Randjelovich T, Krotin M. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases. *Lupus* 2007; 16: 181–5.
130. Bruchfeld A, Goldstein RS, Chavan S, Patel NB, Rosas-Ballina M, Kohn N, Qureshi AR, Tracey KJ. Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. *J Intern Med* 2010; 268: 94-101.
131. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. *J Clin Invest* 2007; 117: 289–296.
132. van Epps HL. Splenic schooling dampens inflammation. *JEM* 2006; 203: 1620a.
133. van der Zanden EP, Boeckxstaens GE, de Jonge WJ. The vagus nerve as a modulator of intestinal inflammation. *Neurogastroenterol Motil* 2009; 21: 6–17.
134. Thayer JF, Sternberg EM. Neural aspects of immunomodulation: focus on the vagus nerve. *Brain, Behav Immun* 2010; 24: 1223-8.
135. Blalock JE. The immune system as the sixth sense. *J Intern Med* 2005; 257: 126–38.
136. Thayer JF, Sternberg EM. Neural concomitants of immunity—focus on the vagus nerve. *Neuroimage* 2009; 47(3): 908–10.

137. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey, KJ. Nicotinic acetylcholine receptor $\alpha 7$ subunit is an essential regulator of inflammation. *Nature* 2003; 421: 384-8.
138. de Jonge WJ, Ulloa L. The $\alpha 7$ nicotinic acetylcholine receptor as a pharmacological target for inflammation. *Br J Pharmacol* 2007; 151: 915–29.
139. Olofsson P, Rosas-Ballina M, Chavan S, Parrish W, Hudson L, Ochani M, Li J, Pavlov V, Tracey K. Long lasting macrophage cytokine suppression by $\alpha 7$ nAChR requires JAK/STAT. *J Immunol* 2010; 184: 138.23.
140. Pacini A, di Cesare Mannelli L, Bonaccini L, Ronzoni S, Bartolini A, Ghelardini C. Protective effect of $\alpha 7$ nAChR: Behavioural and morphological features on neuropathy. *Pain* 2010; 150: 542-9.
141. Borovikova LV, Ivanova S, Nardi D, Zhang M, Yang H, Ombrellino M, Tracey KJ. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. *Auton Neurosci* 2000; 85: 141–7.
142. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, Tracey KJ, Al-Abed Y, Metz CN. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. *J Exp Med* 2005; 201: 1113-23.
143. Oke SL, Tracey KJ. From CNI-1493 to the immunological homunculus: physiology of the inflammatory reflex. *J Leukoc Biol* 2008; 83: 512-7.
144. Johnston GR, Webster NR. Cytokines and the immunomodulatory function of the vagus nerve. *BJA* 2009; 102: 453-62.
145. Valdes-Ferrer S, Rosas-Ballina M, Olofsson, Chavan S, Tracey K. Vagus nerve stimulation produces an anti-inflammatory monocyte phenotype in blood. *J Immunol* 2010; 184: 138.25.
146. Kohr D, Tschernatsch M, Schmitz K, Singh P, Kaps M, Schäfer KH, Diener M,

- Mathies J, Matz O, Kummer W, Maihöfner C, Fritz T, Birklein F, Blaes F. Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen. *Pain* 2009; 143: 246–51.
147. Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, Kummer W, Birklein F, Vincent A, Goebel A, Wallukat G, Blaes F. Autoimmunity against the β_2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. *Pain*; in press, Corrected proof.
148. Sommer C. Anti-autonomic nervous system antibodies in CRPS. *Pain*; in press, Corrected proof.
149. Pavlov VA, Ochani M, Gallowitsch-Puerta M, Ochani K, Huston JM, Czura CJ, Al-Abed Y, Tracey KJ. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. *PNAS* 2006; 103: 5219–23.
150. Goebel A, Baranowski A, Maurer K, Ghiai A, McCabe C, Ambler G. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. *Ann Intern Med* 2010; 152: 152-8.
151. Bernik TR, Friedman SG, Ochani M, DiRaimo R, Susarla S, Czura CJ, Tracey KJ. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. *J Vasc Surg* 2002; 36: 1231-6.
152. Altavilla D, Guarini S, Bitto A, Mioni C, Giuliani D, Bigiani A, Squadrito G, Minutoli L, Venuti FS, Messineo F, De Meo V, Bazzani C, Squadrito F. Activation of the cholinergic anti-inflammatory pathway reduces NF-kappaB activation, blunts TNF-alpha production, and protects against splanchnic artery occlusion shock. *Shock* 2006; 25: 500-6.
153. Yeboah MM, Xue X, Duan B, Ochani M, Tracey KJ, Susin M, Metz CN. Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. *Kidney Int* 2008; 74: 62-9.

154. Guarini S, Altavilla D, Cainazzo MM, Giuliani D, Bigiani A, Marini H, Squadrito G, Minutoli L, Bertolini A, Marini R, Adamo EB, Venuti FS, Squadrito F. Efferent vagal fibre stimulation blunts nuclear factor- κ B activation and protects against hypovolemic hemorrhagic shock. *Circulation* 2003; 107: 1189-94.
155. Guarini S, Cainazzo MM, Giuliani D, Mioni C, Altavilla D, Marini H, Bigiani A, Ghiaroni V, Passaniti M, Leone S, Bazzani C, Caputi AP, Squadrito F, Bertolini A. Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. *Cardiovasc Res* 2004; 63: 357–65.
156. Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllönen E, Lindgren KA, Rantanen P, Tervonen O, Niinimäki J, Seitsalo S, Hurri H. Tumor necrosis factor- α monoclonal antibody, infliximab, used to manage severe sciatica. *Spine* 2003; 28: 750–4.
157. Manning DC. New and emerging pharmacological targets for neuropathic pain. *Curr Pain Headache Rep* 2004; 8: 192-8.
158. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Bowman C, Hammond A, Kirkham B, Järvinen S, Niinimäki J, Veeger N, Haapea M, Torkki M, Tervonen O, Seitsalo S, Hurri H. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. *Spine* 2006; 31: 2759-66.
159. Burnett C, Day M. Recent advancements in the treatment of lumbar radicular pain. *Curr Opin Anaesthesiol* 2008; 21: 452-6.
160. Cohen SP, Bogduk N, Dragovich A, Buckenmaier CC 3rd, Griffith S, Kurihara C, Raymond J, Richter PJ, Williams N, Yaksh TL. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. *Anesthesiology* 2009; 110: 1116-26.

161. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. *N Engl J Med* 2000; 343: 1594–602.
162. Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. *J Pain Symptom Manage* 2004; 27: 101-3.
163. Bernateck M, Rolke R, Birklein F, Treede RD, Fink M, Karst M. Successful intravenous regional block with low-dose tumor necrosis factor- α antibody infliximab for treatment of complex regional pain syndrome 1. *Anesth Analg* 2007; 105: 1148 –51.
164. Kalita J, Vajpayee A, Misra UK. Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial. *QJM* 2006; 99: 89–95.
165. Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. *Acta Chir Scand* 1982; 148: 653–5.
166. Bianchi C, Rossi S, Turi S, Brambilla A, Felisari G, Mascheri D. Long-term functional outcome measures in corticosteroid-treated complex regional pain syndrome. *Eura Medicophys* 2006; 42: 103–11.
167. Braus DF, Krauss JK, Strobel J. The shoulder-hand syndrome after stroke: a prospective trial. *Ann Neurol* 1994; 36: 728-33.
168. Kozin F, Ryan LM, Carerra GF, Soin JS, Wortmann RL. The reflex sympathetic dystrophy syndrome (RSDS). III. Scintigraphic studies, further evidence for the therapeutic efficacy of systemic corticosteroids, and proposed diagnostic criteria. *Am J Med* 1981; 70: 23–30.

169. Grundberg AB. Reflex sympathetic dystrophy: treatment with long-acting intramuscular corticosteroids. *J Hand Surg Am* 1996; 21: 667-70.
170. Glick EN. Reflex dystrophy (algoneurodystrophy): results of treatment by corticosteroids. *Rheumatology* 1973; 12: 84-8.
171. Glick EN, Helal B. Post-traumatic neurodystrophy: treatment by corticosteroids. *Hand* 1976; 8: 45-7.
172. Zyluk A. Results of the treatment of posttraumatic reflex sympathetic dystrophy of the upper extremity with regional intravenous blocks of methylprednisolone and lidocaine. *Acta Orthopaedica Belgica* 1998; 64: 452-6.
173. Poplawski ZJ, Wiley AM, Murray JF. Post-traumatic dystrophy of the extremities. *J Bone Joint Surg Am* 1983; 65: 642-55.
174. Tountas AA, Noguchi A. Treatment of posttraumatic reflex sympathetic dystrophy syndrome (RSDS) with intravenous blocks of a mixture of corticosteroid and lidocaine: a retrospective review of 17 consecutive cases. *J Orthop Trauma* 1991; 5: 412-9.
175. Zyluk A, Puchalski P. Treatment of early complex regional pain syndrome type 1 by a combination of mannitol and dexamethasone. *J Hand Surg Eur Vol* 2008; 33: 130-6.
176. Fischer SGL, Zuurmond WWA, Birklein F, Loer SA, Perez RSGM. Anti-inflammatory treatment of complex regional pain syndrome. *Pain* 2010; 151: 251-6.
177. Birklein F, Sommer C. Intravenous immunoglobulin to fight complex regional pain syndromes: hopes and doubts. *Ann Intern Med* 2010; 152: 188-9.
178. Chandran R, Shen Y, Cantin E. Anti-inflammatory activity of IVIG protects against HSV encephalitis. *J Immunol* 2010; 184: 45.26.
179. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. *N Engl J Med* 1993; 329: 1993-2000.

180. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. *N Engl J Med* 2001; 345: 747-55.
181. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. *J Am Acad Dermatol* 2001; 44: 1010-24.
182. Dalakas MC. Mechanisms of action of IVIG and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. *Neurology* 2002; 59: S13-21.
183. Durelli L, Isoardo G. High-dose intravenous immunoglobulin treatment of multiple sclerosis. *Neurol Sci* 2002; 23: S39–48.
184. Ochi K, Kohriyama T, Higaki M, Ikeda J, Harada A, Nakamura S. Changes in serum macrophage-related factors in patients with chronic inflammatory demyelinating polyneuropathy caused by intravenous immunoglobulin therapy. *J Neurol Sci* 2003; 208: 43-50.
185. Mellick GA, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. *J Pain Symptom Manage* 1995; 10: 265-6.
186. Mellick LB, Mellick GA. Successful treatment of reflex sympathetic dystrophy with gabapentin. *Am J Emerg Med* 1995; 13: 96.
187. Mellick GA, Mellick LB. Reflex sympathetic dystrophy treated with gabapentin. *Arch Phys Med Rehabil* 1997; 78: 98-105.
188. Wheeler DS, Vaux KK, Tam DA. Use of gabapentin in the treatment of childhood reflex sympathetic dystrophy. *Pediatr Neurol* 2000; 22: 220-1.
189. van de Vusse AC, Stomp-van den Berg SGM, Kessels AHF, Weber WE. Randomised controlled trial of gabapentin in complex regional pain syndrome type 1 [ISRCTN84121379]. *BMC Neurol* 2004; 4: 13.

190. Park S, Ahn ES, Han DW, Lee JH, Min KT, Kim H, Hong YW. Pregabalin and gabapentin inhibit substance P-induced NF-kappaB activation in neuroblastoma and glioma cells. *J Cell Biochem* 2008; 105: 414–23.
191. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin – calcium channel $\alpha 2\text{-}\delta$ [Cav $\alpha 2\text{-}\delta$] ligands. *Pain* 2009; 142: 13–6.
192. Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. *Arch Intern Med* 2001; 161: 2502-3.
193. Bengtson K, Rajkumar S, Brault J, Gay R, Jurisson M, Winemiller M, Witzig T. A phase II study of thalidomide in the treatment of chronic complex region pain syndrome (CRPS). *J Pain* 2003; 4: 85 (Poster 936).
194. Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: case report. *J Clin Rheumatol* 2003; 9: 96–8.
195. Prager J, Fleischman J, Lingua G. Open label clinical experience of thalidomide in the treatment of complex regional pain syndrome type I. *J Pain* 2003; 4: 68 (Poster 868).
196. Rajkumar SV, Fonseca R, Witzig TE. Thalidomide has activity in treating complex regional pain syndrome-reply. *Arch Intern Med* 2003; 163: 1488.
197. Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. *Arch Intern Med* 2003; 163: 1487-8.
198. Mackey S, Feinberg S. Pharmacologic therapies for complex regional pain syndrome. *Curr Pain Headache Rep* 2007; 11: 38-43.
199. Manning DC. Immunomodulatory agents for neuropathic pain syndromes: from animals to CRPS and beyond. *Eur J Pain Suppl* 2006; 10: S20-21.
200. Schwartzman RJ, Irving G, Wallace M, Rauck R, Dogra S, Raja S, Cooper A, Faleck H, Zeldis J, Manning D. A multicenter, open label, 12 week study with extension to

- evaluate the safety and efficacy of lenalidomide (CC5013) in the treatment of complex regional pain syndrome type-I. 11th World Congress on Pain. Seattle: IASP Press 2005: 580 (abstract).
201. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF- κ B activation induced by TNF and H₂O₂, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. *J Immunol* 2002; 168: 2644-51.
 202. Teo SK, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Thalidomide in the treatment of leprosy. *Microbes Infect* 2002; 4: 1193-202.
 203. Sinis N, Birbaumer N, Schwarz A, Gustin S, Unertl K, Schaller HE, Haerle M. Memantine und komplexes regionales Schmerzsyndrom (CRPS): Behandlungseffekte und kortikale Reorganisation (Memantine and complex regional pain syndrome (CRPS): effects of treatment and cortical reorganisation). *Handchir Mikrochir Plast Chir* 2006; 38: 164-71 (in German).
 204. Sinis N, Birbaumer N, Gustin S, Schwarz A, Bredanger S, Becker ST, Unertl JK, Schaller H-E, Haerle M. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. *Clin J Pain* 2007; 23: 237-43.
 205. Gustin SM, Schwarz A, Birbaumer N, Sinis N, Schmidt AC, Veit R, Larbig W, Flor H, Lotze M. NMDA-receptor antagonist and morphine decrease CRPS-pain and cerebral pain representation. *Pain* 2010 (in press).
 206. Tsartsalis S, Tomos C, Karanikola T, Mironidou-Tzouveleki M. The effect of memantine on cerebral cortex tumor necrosis factor alpha expression in a rat model of acute hyperammonemia. *Ann Gen Psychiatry* 2010; 9(S1): S181.
 207. Perez RS, Zuurmond WW, Bezemer PD, Kuik DJ, van Loenen AC, de Lange JJ, Zuidhof AJ. The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study. *Pain* 2003; 102: 297-307.

208. Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. *Pharm Res* 1995; 12: 916-22.
209. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, Heickendorff L, Eriksen EF, Nielsen JL. Long term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. *Eur J Haematol* 1998; 61: 128-34.
210. Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate. *J Pediatr Hematol Oncol* 2001; 23: 54-6.
211. Danenberg HD, Fishbein I, Gao J, Mönkkönen J, Reich R, Gati I, Moerman E, Golomb G. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. *Circulation* 2002; 106: 599-605.
212. Maksymowych WP. Bisphosphonates – anti-inflammatory properties. *Curr Med Chem – Anti-Inflammatory & Anti-Allergy Agents* 2002; 1: 15-28.
213. Huk OL, Zukor DJ, Antoniou J, Petit A. Effect of pamidronate on the stimulation of macrophage TNF-alpha release by ultra-high-molecular-weight polyethylene particles: a role for apoptosis. *J Orthop Res* 2003; 21: 81-7.
214. Breuer B, Pappagallo M, Ongseng F, Chen CI, Goldfarb R. An open-label pilot trial of ibandronate for complex regional pain syndrome. *Clin J Pain* 2008; 24: 685–9.
215. Devogelaer JP, Dall’Armellina S, Huaux JP, Nagant de Deuxchainaisnes C. Dramatic improvement of intractable reflex sympathetic dystrophy syndrome by intravenous infusions of the second generation bisphosphonate APD. *J Bone Miner Res* 1988; S3: 122.

216. Rehman MTA, Clayson AD, Marsh D, Adams J, Cantrill J, Anderson DC. Treatment of refractory reflex sympathetic dystrophy with intravenous pamidronate. *Bone* 1992; 13: 116 (abstract).
217. Maillefert JF, Chatard C, Owen S, Peere T, Tavernier C, Tebib J. Treatment of refractory reflex sympathetic dystrophy with pamidronate. *Ann Rheum Dis* 1995; 54: 687.
218. Adami S, Fossaluzza V, Gatti D, Fracassi E, Braga V. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. *Ann Rheum Dis* 1997; 56: 201–4.
219. Cortet B, Flipo RM, Coquerelle P, Duquesnoy B, Delcambre B. Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. *Clin Rheumatol* 1997; 16: 51–6.
220. Maillefert JF, Cortet B, Aho S. Pooled results from 2 trials evaluating bisphosphonates in reflex sympathetic dystrophy. *J Rheumatol* 1999; 26: 1856–7.
221. Varenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P, Sinigaglia L. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome: a randomized, double blind, placebo controlled study. *J Rheumatol* 2000; 27: 1477–83.
222. Kubalek I, Fain O, Paries J, Kettaneh A, Thomas M. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. *Rheumatology (Oxford)* 2001; 40: 1394–7.
223. Manicourt D-H, Brasseur J-P, Boutsen Y, Depreseux G, Devogelaer JP. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. *Arthritis Rheum* 2004; 50: 3690–7.
224. Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type I. *Pain Med* 2004; 5: 276-80.
225. Chauvineau V, Codine P, Hérisson C, Pellas F, Pélissier J. Quelle est la place des biphosphonates dans le traitement de l'algodystrophie sympathique réflexe?: Analyse

- critique de la littérature (What is the place of biphosphonates in the treatment of complex regional pain syndrom I?: A literature review). *Ann Readapt Med Phys* 2005; 48: 150-7 (in French).
226. Gremeaux V, Hérissou C, Péliissier J. Complex regional pain syndrome of the knee: early and beneficial action of diphosphonates on pain and function. *Ann Readapt Med Phys* 2007; 50: 240-3 (in French).
 227. Brunner F, Schmid A, Kissling R, Held U, Bachmann LM. Biphosphonates for the therapy of complex regional pain syndrome I - systematic review. *Eur J Pain* 2009; 13: 17–21.
 228. Cassisi G, Sartori L. Efficacy of intramuscular clodronate in complex regional pain syndrome type I: description of a case located in the astragalus in a patient with psoriatic arthritis. *Acta Biomed* 2009; 80: 268-77.
 229. Santamato A, Ranieri M, Panza F, Solfrizzi V, Frisardi V, Stolfa I, Megna M, Fiore P. Role of biphosphonates and lymphatic drainage type Leduc in the complex regional pain syndrome (shoulder-hand syndrome). *Pain Med* 2009; 10: 179-85.
 230. Perez RS, Zollinger PE, Dijkstra PU, Thomassen-Hilgersom IL, Zuurmond WW, Rosenbrand KCJ, Geertzen JH, the CRPS I task force. Evidence based guidelines for complex regional pain syndrome type 1. *BMC Neurology* 2010; 10: 20.
 231. Simm PJ, Briody J, McQuade M, Munns CF. The successful use of pamidronate in an 11-year-old girl with complex regional pain syndrome: response to treatment demonstrated by serial peripheral quantitative computerised tomographic scans. *Bone* 2010; 46: 885-8.
 232. Tran De Q H, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: a review of the evidence. *Can J Anesth/J Can Anesth* 2010; 57: 149–66.

233. Khattab K, Khattab AA, Ortak J, Richardt G, Bonnemeier H. Iyengar yoga increases cardiac parasympathetic nervous modulation among healthy yoga practitioners. *Evid Based Complement Alternat Med* 2007; 4: 511–7.
234. Brown RP, Gerbarg PL. Yoga breathing, meditation, and longevity. *Ann N Y Acad Sci* 2009; 1172: 54-62.
235. Oke SL, Tracey KJ. The inflammatory reflex and the role of complementary and alternative medical therapies. *Ann NY Acad Sci* 2009; 1172: 172-80.
236. Stanton-Hicks M. Plasticity of complex regional pain syndrome (CRPS) in children. *Pain Med* 2010; 11: 1216–23.

Figure legends

Figure 1. Effects of an over-supply of TNF on symptoms of CRPS. The blue arrows represent pathways for the prolonged manufacture of TNF and other inflammatory mediators, and for the production of symptoms. A deficit in sympathetic vasoconstrictor regulation that results in microcirculatory ischaemia and hypoxia may augment necrosis in local tissues (red arrows). Inhibition of N-type calcium channel currents in sympathetic vasoconstrictor fibres (orange arrows) could further aggravate this cycle.

Figure 2. The cholinergic anti-inflammatory pathway. Under normal conditions, inflammatory mediators detected by vagal afferent fibres activate vagal efferent fibres with cell bodies in the dorsal motor nucleus and nucleus ambiguus. This prevents the production of TNF (blue arrows). However, failure of this inhibitory process could contribute to heightened production of TNF and “sterile” inflammation (red arrows).

Table 1. Drug trials that target an action of TNF (and other primary mechanisms) in CRPS *

	Diagnosis	Design	Intervention	N	Patient details including age, gender, duration of painful CRPS and inciting event	Results including the number of patients that benefited from intervention via reduced pain and other clinical benefits
Infliximab (a therapeutic monoclonal antibody that selectively targets TNF)						
Huygen et al. [162]	CRPS type 1	Case reports	Infliximab	2	<p>Case 1: F, 50</p> <p>Spontaneous onset of CRPS in left leg 5 years earlier, followed by CRPS in right leg 2 years later.</p> <p>Case 2: F, 55</p> <p>Acute CRPS caused by a left Colles' fracture 2 months earlier (resulting in affected limb being casted for 2 months).</p>	Infliximab treatment of <1 month led to decreased localized TNF and IL-6 in blister fluid. Amelioration of CRPS symptoms including pain, temperature, edema and motor dysfunction occurred in both patients.
Bernateck et al. [163]	CRPS type 1	Case report	Infliximab	1	F, 62. Acute CRPS caused by a left Colles' fracture 3 months earlier.	Near complete remission following infliximab treatment for 8 weeks.
Trial Register 449 ISRCTN 75765780	CRPS type 1	Controlled trial	Infliximab (n=7) Placebo (n=6)	7	Aged 18 - 65	Positive results for infliximab-treated patients, compared to placebo group.
** Corticosteroids (corticosteroid treatment inhibits local inflammation and serum TNF [15])						

Wasner et al. [93]	CRPS type 1	Case report	Treatment also included sympatholytic blocks, NSAIDs and physiotherapy for 6 weeks.	1	F, 52. Acute CRPS in right forearm and hand (following right distal radius fracture and plaster).	Full recovery from CRPS within one year, post fracture.
Kalita et al. [164]	Patients who developed CRPS after stroke	Randomized controlled trial	Corticosteroids (prednisolone) for up to one month (n=30). Control patients received NSAID (piroxican) (n=30). Both groups underwent ongoing physiotherapy.	60	CRPS developed within 7 to 100 days following stroke in all 60 patients (40 males, 20 females; 40 - 70 years; mean age=56)	25/30 (83.3%) CRPS patients benefited significantly from daily corticosteroid (oral prednisolone) treatment, compared with 5 of 30 (16.7%) CRPS patients following NSAID (piroxican) treatment.
Bianchi et al. [166]	CRPS	Case reports	Corticosteroids (prednisone)	25	Various	21 of 25 CRPS patients derived lasting benefits following corticosteroid treatment.
Braus et al. [167]	Shoulder-hand syndrome after stroke in hemiplegic patients	Randomized placebo-controlled non blinded trial	Corticosteroids (oral methylprednisolone)	36	Various	31 patients became 'almost symptom free' following daily low doses of corticosteroids (oral methylprednisolone) for up to 10 days.
Kozin et al. [168]	RSD	Comparative non-randomized	Comparison of systemic oral prednisone (n=35) to stellate ganglion	55	Various	Prednisone treatment resulted in 'excellent' results for 14 patients (40%) and 'good' results for 8 patients (23%). However, 17 patients had 'poor' results

		study	blockade (n=20)			and 3 patients had only 'fair' results following stellate ganglion blocks (n=20).
Grundberg [169]	RSD	Case reports	Corticosteroids (methylprednisolone injections)	69	Various	47 of 69 patients obtained significant benefits.
Christensen et al. [165]	Acute RSD	Randomized placebo-controlled trial	Corticosteroids (oral prednisone for a maximum of 12 weeks) (n=13). Placebo (n=10).	23	22/23 had sustained a fracture while 1 had an abscess following an incision. Mean duration from trauma to RSD diagnosis was 92 days (range 50-194 days).	All 13 patients in the prednisone treatment group showed greater than 75% clinical improvement within 12 weeks.
Glick [170]	RSD (acute and chronic)	Case reports	Corticosteroids	17	RSD caused by elbow injury (n=4), post surgery (n=3), wrist fracture (n=1), finger injury (n=1), leg injury (n=1) and shoulder-hand syndrome (n=7).	12 of 17 RSD patients had fair to excellent results following daily corticosteroid treatment for 10-70 weeks.
Glick & Helal [171]	Post-traumatic neuro-dystrophy	Case reports	All patients were given daily oral prednisolone for 6-8 months except for 2 patients who received intramuscular methylprednisolone	21	Various	10 had 'very good' results (pain relief and good movement) and 3 had 'good' results (limited pain requiring nil analgesics and some movement).
Zyluk [172]	Painful RSD of upper limb	Case reports	A solution of methylprednisolone, lidocaine and heparin was injected	36	23 females; 13 males; 44-73 years. RSD-inciting events included distal radius fracture (n=22), fasciectomy (n=5)	At 1-year follow-up, 25 patients (69%) reported 'good' relief of spontaneous pain and normal finger movements.

			into the dorsal side of the affected hand or wrist, and a 20-25 minute occlusion block was maintained.		and other hand injuries (n=9). RSD duration was less than 1 year in all cases.	
Poplawski et al. [173]	Post-traumatic dystrophy of the extremities	Case reports	Regional IV blocks involving a solution of corticosteroid (methylprednisolone and lidocaine for ~30 minutes)	27	13 males; 14 females; aged 31- 81 years. Duration ranged from 2-36 months	10 patients (11 limbs) had 'excellent' results that included little or no pain and edema as well as a full range of motion. Five patients obtained 'good' or 'very good' results, and required nil or infrequent analgesia.
Tountas & Noguchi [174]	RSD	Case reports	Regional IV blocks involving a solution of corticosteroid (methylprednisolone sodium succinate) and lidocaine	17	Inciting event included distal radius fracture Duration ranged from 2 days to almost 6 months.	At 6 months, 11 patients showed complete or almost complete relief from symptoms.
Zyluk & Puchalski [175]	Acute CRPS type I	Case reports	Mannitol and dexamethasone combination treatment (daily for 1 week)	75	75 patients (68 females; 7 males; aged 38-82; Duration less than 4 months. Various inciting events.	After 1-week treatment, pain from a mean Visual Analogue Scale (VAS) dropped from 6.7 to 2.3. After 8-12 months, at the final assessment, 70 patients had a mean VAS of 1.8. Other variables also improved significantly.
Thalidomide or lenalidomide (these agents act intracellularly, resulting in inhibited production of TNF and other cytokines) [193,194]						
Rajkumar et al. [192,196]	RSD	Case report	Thalidomide	1	F, 43 3 years duration.	After 1-month thalidomide treatment RSD was almost entirely resolved, and the leg

					Caused by traumatic injury to her left hand.	ulcer and edema were completely healed. The patient no longer needed her wheelchair and walked normally. She no longer took pain medication and regained function in her left hand several months later. When the patient was followed up 30 months later, she remained free of CRPS.
Schwartzman et al. [197]	CRPS	Case reports	Thalidomide	42	Long-standing CRPS disease.	7 (17%) patients showed a ‘dramatic response’ following thalidomide treatment, while 6 (14%) patients had ‘modest pain relief’ and/or reduced their pain medication.
Ching et al. [194]	CRPS type 1	Case report	Thalidomide	1	F, 33. CRPS caused by a fall on left knee 6 years earlier	CRPS pain in her left knee disappeared, post thalidomide treatment.
Bengtson et al. [193]	Chronic upper limb CRPS	Phase II trial	Thalidomide	12	CRPS duration exceeded 1 year in all patients	Thalidomide treatment for 6 months resulted in significant pain reduction in 4 patients.
Prager et al. [195]	CRPS type 1	Case reports	Thalidomide	9	2 males, 7 females	Pain decreased significantly in 7 of 9 patients after thalidomide treatment.
Manning [199]	CRPS type 1	Case reports	Lenalidomide	40	Genders/ages not specified	14 of 40 patients took oral lenalidomide treatment for >2 years. These patients showed overall improvement in symptoms including improvements in pain, allodynia and sleep.
Schwartzman et al. [200]	Chronic CRPS type	Case reports	Lenalidomide. Multicenter (6	40	Average duration 6 years, 75% female	Daily oral lenalidomide treatment resulted in sustained symptom reduction including

1

centers), open label, 12-week study (the core phase), plus option to extend for a further 40 weeks

pain reduction in all 31 patients that completed the core phase. 18 (of 31) also completed the extended 40-week period (and continued into 2nd year of treatment.

Intravenous immunoglobulin (macrophage Fc receptor inhibition may suppress TNF production and reduce endothelial cell activation [174], and also neutralize autoantibody effects in some autoimmune diseases [176])

Goebel et al. [150]	CRPS	Randomized, double-blind, placebo-controlled crossover trial	Intravenous immunoglobulin	13	6 to 30 months duration. Various inciting events	3 of 12 CRPS patients who completed the trial had significant pain relief following intravenous immunoglobulin therapy.
---------------------	------	--	----------------------------	----	---	---

Gabapentin and pregabalin (bind with the $\alpha 2\delta 1$ calcium channel subunit. In addition to decreased neurotransmitter release, this may inhibit translocation of NF κ B into the cell nucleus and decrease the production of inflammatory agents including TNF [34,38,182,183])

Mellick & Mellick [187]	RSD	Case reports	Gabapentin	6	42-68 years, all female. Various durations/ inciting events	Pain reduction ranged from 85% to 100% in 5 patients and 60% in the other patient.
Wheeler et al. [188]	Childhood RSD (acute)	Case report	Gabapentin	1	Girl, 9 years. Inciting event: ingrown nail with purulent drainage in left big toe	Complete resolution of all CRPS symptoms following gabapentin treatment.

Memantine (in addition to effects on NMDA and other receptors/channels [195,196,197], memantine may decrease TNF expression [198])

Sinis et al. [203]	CRPS	Case reports	Oral memantine for 8 weeks	3	F, 60; M, 58; M, 49. CRPS duration 1-7 months; various trauma-inciting events	Nil 'resting' pain was present in 3 patients at the 6 month follow-up.
--------------------	------	--------------	----------------------------	---	---	--

Sinis et al. [204]	CRPS	Case reports	Memantine	6	4 men and 2 women (29-64 years; mean age 48.3 years). CRPS duration: 4-23 months; various trauma-inciting events	Pain decreased significantly and 'continuous' pain was abolished in 6 patients after 8 weeks of memantine treatment (as reported at the 6 month follow-up). This was accompanied by an improvement in motor symptoms and autonomic changes in all patients.
Gustin et al. [205]	CRPS	Double-blind randomized placebo-controlled study	Memantine + morphine (n=10) Placebo + morphine (n=10)	20	8 men and 12 women; 29-69 years; mean age 50.9 years. CRPS duration 6-36 months; various trauma-inciting events	Pain decreased significantly in 10 CRPS patients after the memantine/morphine combination treatment for 8 weeks.
N-acetylcysteine (a free radical scavenger [199] that may also inhibit NFκB and cytokine production including TNF [39,41])						
Perez et al. [207]	CRPS type 1	Randomized actively controlled trial	CRPS patients were randomly assigned to either N-acetylcysteine (n=74) or DMSO (n=71) for 17 weeks (regardless whether they were 'warm' or 'cold' CRPS).	74	20 males; 54 females; mean age 48.94 years; 18 'cold' CRPS patients and 56 'warm' CRPS patients. Median duration of CRPS pain: 102 days.	The 18 'cold' CRPS patients benefited from N-acetylcysteine treatment whereas the 56 'warm' CRPS patients did not.

*Bisphosphonate treatment for CRPS may also exert inhibitory effects on TNF production, but these studies are not included in the table.

**Additional corticosteroid-related studies were reviewed by Fischer et al. [167].